By Cecilia Butini

 

Merck KGaA said Wednesday that it would invest 59 million euros ($69.5 million) in expanding its manufacturing capabilities, and capacity for high-potent active pharmaceutical ingredients and antibody-drug conjugates at its U.S. facility near Madison, Wisc.

The German pharmaceuticals and chemicals company said the investment would allow manufacturing of compounds for therapies which have the potential to treat cancer, and it would create roughly 50 full-time jobs starting in 2021.

Completion of the expansion--which consists of a 6,500-square-meter commercial building--is expected by mid-2022, the company said.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

September 09, 2020 10:55 ET (14:55 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Merck KGaA (PK) Charts.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Merck KGaA (PK) Charts.